Mexico Newborn Screening Market Size & Outlook, 2023-2030
Mexico newborn screening market, 2018-2030 (US$M)
Related Markets
Mexico newborn screening market highlights
- The Mexico newborn screening market generated a revenue of USD 18.8 million in 2023 and is expected to reach USD 28.7 million by 2030.
- The Mexico market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2023.
- Tandem Mass Spectrometry is the most lucrative technology segment registering the fastest growth during the forecast period.
Newborn screening market data book summary
| Market revenue in 2023 | USD 18.8 million |
| Market revenue in 2030 | USD 28.7 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Tandem mass spectrometry |
| Fastest growing segment | Tandem Mass Spectrometry |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-based Assay, DNA Assays, Electrophoresis |
| Key market players worldwide | Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp |
Other key industry trends
- In terms of revenue, Mexico accounted for 2.4% of the global newborn screening market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Mexico newborn screening market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 27.4 million by 2030.
Tandem mass spectrometry was the largest segment with a revenue share of 25% in 2023. Horizon Databook has segmented the Mexico newborn screening market based on tandem mass spectrometry, pulse oximetry, enzyme-based assay, dna assays, electrophoresis covering the revenue growth of each sub-segment from 2018 to 2030.
According to the National Law passed in 2005, all of the neonates require screening for hearing impairments and other congenital anomalies. In 2008, PerkinElmer along with the Ministry of Health agreed to expand the NBS program three folds in order to increase the capacity.
PerkinElmer provided the laboratories with instruments, reagents, and other consumables needed along with training and consultations with experts. They particularly provided the DELFIA Neonatal TSH kit for detection of congenital hypothyroidism. In 2009, the Audiology Department of Ministry of Health lined up funds to allocate screening instrumentation in 300 institutions.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Newborn Screening Market Scope
Newborn Screening Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico newborn screening market size, by technology, 2018-2030 (US$M)
Mexico Newborn Screening Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
